Maintenance of p-eIF2α levels by the eIF2B complex is vital for colorectal cancer

eIF2B复合物维持p-eIF2α水平对结直肠癌至关重要。

阅读:1
作者:Ivana Paskov Škapik # ,Chiara Giacomelli # ,Sarah Hahn ,Hanna Deinlein ,Peter Gallant ,Mathias Diebold ,Josep Biayna ,Anne Hendricks ,Leon Olimski ,Christoph Otto ,Carolin Kastner ,Elmar Wolf ,Christina Schülein-Völk ,Katja Maurus ,Andreas Rosenwald ,Nikolai Schleussner ,Rene-Filip Jackstadt ,Nicolas Schlegel ,Christoph-Thomas Germer ,Martin Bushell ,Martin Eilers ,Stefanie Schmidt ,Armin Wiegering
Protein synthesis is an essential process, deregulated in multiple tumor types showing differential dependence on translation factors compared to untransformed tissue. We show that colorectal cancer (CRC) with loss-of-function mutation in the APC tumor suppressor depends on an oncogenic translation program regulated by the ability to sense phosphorylated eIF2α (p-eIF2α). Despite increased protein synthesis rates following APC loss, eIF2α phosphorylation, typically associated with translation inhibition, is enhanced in CRC. Elevated p-eIF2α, and its proper sensing by the decameric eIF2B complex, are essential to balance translation. Knockdown or mutation of eIF2Bα and eIF2Bδ, two eIF2B subunits responsible for sensing p-eIF2α, impairs CRC viability, demonstrating that the eIF2B/p-eIF2α nexus is vital for CRC. Specifically, the decameric eIF2B linked by two eIF2Bα subunits is critical for translating growth-promoting mRNAs which are induced upon APC loss. Depletion of eIF2Bα in APC-deficient murine and patient-derived organoids establishes a therapeutic window, validating eIF2Bα as a target for clinical intervention. In conclusion, we demonstrate how the expression of the oncogenic signature in CRC is crucially controlled at the translational level.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。